This partnership
is personal

Genomic solutions to change how cancer will be identified and treated

Future of NGS in Oncology

As genomics-focused pharmacology begins to play a greater role in cancer treatment, next-generation sequencing (NGS) is emerging as a valuable method for obtaining a deeper and more accurate look into the molecular underpinnings of individual tumors. With targeted therapies becoming the new standard of care in oncology, NGS-driven companion diagnostics are widely seen as driving the selection of treatments to optimize patient outcomes in the future.

Compared to traditional methods, NGS offers advantages in accuracy, sensitivity, and speed that has the potential to make a significant impact on the field of oncology. Because NGS can assess multiple genes in a single assay, it eliminates the need to order multiple tests to identify the causative mutation.

This multigene approach decreases the time to answer, providing a more economical solution and reducing the risk of exhausting precious clinical samples. In addition, NGS can provide high sensitivity, enabling the detection of mutations present at as little as 5% of the DNA isolated from a tumor sample.

NGS has the potential to change the future of oncology and advance the promise of personalized medicine. We invite you to learn more by examining the resources collected here.

Oncology
Introduction to NGS in Oncology

Learn more about how NGS technology works and the advantages it offers over traditional methods in these in-depth introductions tailored to oncologists and molecular pathologists.

Introduction to NGS in Oncology

Based on the content of TruSight Oncology 500, the proposed Illumina in vitro diagnostic will receive prioritized review and resources.

Read Article
The FDA Grants Breaakthrough Device Designation for Illumina's TruSight Assay
TruSight Oncology Family Grows with Liquid Biopsy and High-Throughput Assays
TruSight Oncology Family Grows with Liquid Biopsy and High-Throughput Assays

Providing customers with a versatile, scalable, sample-to-report workflow

Read Article
The Changing Landscape of NGS Implementation in Molecular Diagnostic Laboratories
The Changing Landscape of NGS Implementation in Molecular Diagnostic Laboratories

Key opinion leaders discuss the ongoing challenges and potential of NGS in oncology testing.

Read Interview
Patients With Challenging Cancers to Benefit from Genomic Sequencing
Patients With Challenging Cancers to Benefit from Genomic Sequencing

University of Melbourne and Illumina Target Diagnosis of Difficult Cancers

Read Article
See More Cancer-Specific Content and Products

The user-friendly "Recommended Links" feature allows you to easily find content and products relevant to cancer and/or a variety of other fields. You can access this option from the top of any illumina.com page.

Learn How
Scientists Pipetting and Viewing a Computer
Tumor Mutational Burden (TMB)

NGS can help clinical researchers estimate TMB, identify neoantigens, and study innovative therapies to boost the immune response.

Learn More
ctDNA Sequencing

NGS offers the sensitivity and specificity that clinical researchers need to detect low levels of circulating tumor DNA (ctDNA) in the bloodstream.

Learn More
Cancer Epigenetics

Explore the benefits of NGS and microarrays for analyzing altered methylation patterns and other epigenetic changes in cancer.

Learn More
Interested in receiving newsletters, case studies, and information on cancer genomics? Enter your email address.
Image
Genomic Applications in Oncology

The Medical Affairs team at Illumina discusses the applications of genomics in oncology for risk prediction and precision medicine.

Learn More
Francis deSouza Speaks at Aspen Ideas: Health
Francis deSouza Speaks at Aspen Ideas: Health

Francis deSouza, President and CEO of Illumina, shares his views on actions needed to bring genomics to the patients who need it.

Read Article
Image
Medical Genetics Education

Find educational resources about medical genetics and learn how genomic information can be used in clinical practice.

Learn More